GlycoVaxyn Winner of the Swiss Life Sciences Prize 2006
The Swiss Life Sciences Prize 2006 was awarded to the company GlycoVaxyn AG. The prize of CHF 10'000, awarded for the third time, stands under the patronage of the Swiss Biotech Association and BioValley Basel, and is intended for young Swiss companies in the Pharma and Medtech sectors.
GlycoVaxyn, a spin-off company of the ETH Zürich, is developing novel conjugated vaccines. According to the company, over the last 20 years, such highly efficient vaccines have provided safe immunizations in humans. Their manufacturing involves a complex chemical conjugation step, which is circumvented by GlycoVaxyn's technology, where recombinant Escherichia coli bacteria link antigenic sugar chains, which originate from the cell surface of pathogenic bacteria, in vivo to carrier proteins. This biotechnological process will be developed to the point where novel conjugated vaccines offer dependable protection at an affordable prize.
Meistgelesene News
Weitere News aus dem Ressort Wirtschaft & Finanzen
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Holen Sie sich die Analytik- und Labortechnik-Branche in Ihren Posteingang
Ab sofort nichts mehr verpassen: Unser Newsletter für Analytik und Labortechnik bringt Sie jeden Dienstag auf den neuesten Stand. Aktuelle Branchen-News, Produkt-Highlights und Innovationen - kompakt und verständlich in Ihrem Posteingang. Von uns recherchiert, damit Sie es nicht tun müssen.